Simulations Plus, Inc.

Simulations Plus, Inc.

SLPNYSE / NASDAQHealthcareSmall cap

$18.50$0.00 (0.0%)

Last close · Data as of Oct 7, 2026

Market cap
$336.4M
P/E
-5.2x
EV / EBITDA
20.8x
Revenue
$79.2M
Net margin
-81.7%
ROCE
5.2%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Simulations Plus, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 7 Oct 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $18.50 to $18.50 · Last close Oct 7, 2026

Best weekday to invest, historically

The same weekly amount in SLP, bought on each weekday since 2021.

News & filings

What Simulations Plus filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 64.7 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.67 times current liabilities.
  • Prices are as of 7 Oct 2026; price-based points are paused until newer prices arrive.

Prices to the 7 Oct 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments.

Read moreShow less

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Sector
Healthcare
Shares outstanding
20.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$336.4M
P/E
-5.2x
P/B
2.7x
EV / EBITDA
20.8x
EV / Sales
3.9x
P/S
4.2x
52-week high
$20.84
52-week low
$11.36

Profitability

Operating margin
8.2%
Net margin
-81.7%
EBITDA margin
18.6%
ROE
-51.9%
ROCE
5.2%
ROIC
5.4%
ROA
-49.1%
Asset turnover
0.60

Growth

Revenue
$79.2M
Revenue growth, 1Y
13.1%
Revenue CAGR, 3Y
13.7%
Net profit growth, 1Y
-750.2%
Free cash flow
$14.4M

Solvency

Current ratio
7.67
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
-0.28
Cash / Market cap
9.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$79.2M
Cost of revenue$33.0M
Gross profit$46.2M
Operating expenses$39.7M
Research and development$6.9M
Selling, general and administrative$32.8M
Operating income$6.5M
Interest and other-$75.9M
Pretax income-$69.4M
Tax and other-$4.7M
Net income-$64.7M

Revenue and net profit

Revenue grew 13.1% in FY2025; net profit is the dashed line.

Simulations Plus, Inc. revenue and net profit by fiscal year
Simulations Plus, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$53.9M$12.5M
FY2023$59.6M$10.0M
FY2024$70.0M$10.0M
FY2025$79.2M-$64.7M

Cash flows

FY2025: $18.1M from operations, $14.4M free after investment (dashed).

Simulations Plus, Inc. operating and free cash flow by fiscal year
Simulations Plus, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$17.9M$13.9M
FY2023$21.9M$17.6M
FY2024$13.3M$9.0M
FY2025$18.1M$14.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$79.2M+13.1%1Y
EBITDA
$14.7M+24.6%1Y
Net profit
-$64.7M-750.2%1Y
Cash from operations
$18.1M+36.1%1Y
Free cash flow
$14.4M+59.7%1Y
Revenue CAGR, 3Y
13.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$79.2M$14.7M-$64.7M$14.4M-51.9%+13.1%-750.2%

Monthly returns

Month-by-month returns of SLP across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$131.9M
Liabilities$7.1M
Equity$124.8M
Paid-in capital$159.4M
Retained earnings-$34.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SLP highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Simulations Plus, Inc. (this company)3.9x

Not shown (no positive earnings and no EV / Sales): Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Simulations Plus, Inc.SLPthis company$336.4M-5.2x2.7x-51.9%20.8x
Atea Pharmaceuticals, Inc.AVIR$353.7M-2.2x1.3x-57.5%-1.4x
Greenwich LifeSciences, Inc.GLSI$347.1M-22.0x137.0x-623.1%—
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Peer median—-2.2x4.8x-169.4%-3.3x

Year-to-date ROI

SLP since 1 January, against earlier years.

Historical volatility

SLP's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Simulations Plus, Inc. operating margin by fiscal year
Simulations Plus, Inc. operating margin by fiscal year
DateOperating margin
FY202227.7%
FY202315.5%
FY20248.8%
FY20258.2%
LineFY2025
Cost of revenueCost Of Revenue$33.0M
Gross profitGross Profit$46.2M
Operating expensesOperating Expense$39.7M
Research and developmentResearch And Development$6.9M
Total expensesTotal Expenses$72.7M
Pretax incomePretax Income-$69.4M

Learn while you research

Academy chapters picked for Simulations Plus, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →